3 ms·
You could argue that overall we’re seeing either no benefit or some benefit here, which is good As expected, no blockbuster. There are concerns about patient r
by HarryHirsch 7y ago
You could argue that overall we’re seeing either no benefit or some benefit here, which is good
As expected, no blockbuster. There are concerns about patient recruitment and endpoints as well. We'll have to wait for antivirals.
- sfj 7y agoThey didn't try it along with Azithromycin. With this included, the most promising results were observed in the prior studies.